What is Code Bio?
Founded in 2020 and headquartered in Philadelphia, PA, Code Bio is at the forefront of developing advanced gene therapy treatments. The company's proprietary non-viral gene delivery system is designed to overcome key limitations of existing gene therapy approaches, offering a potentially safer and more effective method for treating severe genetic disorders. Code Bio's technology holds promise for addressing diseases with complex genetic mutations, positioning the company as a key player in the rapidly evolving landscape of precision medicine and rare disease therapeutics.
How much funding has Code Bio raised?
Code Bio has raised a total of $85M across 2 funding rounds:
Angel/Seed
$10M
Series A
$75M
Angel/Seed (2021): $10M with participation from Takeda Pharmaceutical, JDRF T1D Fund, UPMC, New Enterprise Associates, 4BIO Capital, and CureDuchenne
Series A (2022): $75M led by New Enterprise Associates, 4BIO Capital, Northpond Ventures, Amgen Business Development, CureDuchenne Ventures, UCB Ventures, Hatteras Venture Partners, Takeda, JDRF T1D Fund, and UPMC
Key Investors in Code Bio
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, known for its focus on supporting entrepreneurs in building impactful businesses across various sectors.
4BIO Capital
4BIO Capital is a London-based venture capital firm specializing in life sciences, with a strategic focus on advanced therapies like gene and cell therapy aimed at addressing significant unmet medical needs.
Amgen Business Development
Amgen Oncology is dedicated to advancing cancer treatment through innovative therapies and patient care, leveraging extensive experience to deliver high-quality biosimilar medicines and improve patient outcomes.
What's next for Code Bio?
With this substantial backing, Code Bio is poised to accelerate the development and clinical translation of its gene delivery platform. The strategic investment will likely fuel further research and development initiatives, expand the company's scientific team, and advance its pipeline programs toward clinical trials. This financing round signals a critical growth phase for Code Bio, enabling the company to pursue its mission of bringing transformative gene therapies to patients suffering from unmet medical needs, reinforcing its position in the competitive biotech sector.
See full Code Bio company page
